Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Creon After Pancreatic Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00535756
Recruitment Status : Completed
First Posted : September 26, 2007
Last Update Posted : August 18, 2011
Quintiles, Inc.
Data Map GmbH
Information provided by:

Brief Summary:
This study will provide efficacy data for Creon 25000 MMS in PS patients as well as long-term safety data. During the long-term treatment with Creon 25000 nutritional parameters will be assessed and correlated with CFA

Condition or disease Intervention/treatment Phase
Pancreatic Insufficiency Drug: Creon Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 58 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: One Week Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center Study With Creon® 25000 Minimicrospheres™ in Subjects With Pancreatic Exocrine Insufficiency After Pancreatic Surgery, Followed by an Open-Label Long-Term Extension of 1 Year
Study Start Date : April 2008
Actual Primary Completion Date : June 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1 Drug: Creon
3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)

Placebo Comparator: 2 Drug: Placebo

Primary Outcome Measures :
  1. Change in CFA from baseline to the end of double blind treatment [ Time Frame: 7 days after baseline ]

Secondary Outcome Measures :
  1. CNA, stool fat, stool weight, nutritional parameters, clinical symptomatology, SF-36, BMI [ Time Frame: 7 days after baseline, and end of open-label period (1 year of open label treatment) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Pancreatic exocrine insufficiency has to be proven (in medical history) by the following criteria:

  • Direct or indirect pancreatic function test (except stool fat excretion) and
  • Steatorrhoea: stool fat > 15 g/day (using van de Kamer method)
  • Proven chronic pancreatitis
  • Females of child-bearing potential must agree to continue using a medically acceptable method of birth control

Exclusion Criteria

  • Subjects in an unstable situation (catabolic) after pancreatic surgery
  • Ileus or acute abdomen
  • Current excessive intake of alcohol or drug abuse
  • Hypersensitivity vs porcine proteins / pancreatin
  • Subjects taking digestive enzyme preparations have to stop them before start of the run-in period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00535756

Layout table for location information
Site Reference ID/Investigator# 45022
Ruse, Bulgaria, 7002
Site Reference ID/Investigator# 45020
Sofia, Bulgaria, 1233
Site Reference ID/Investigator# 45026
Greifswald, Germany, MV 17475
Site Reference ID/Investigator# 45025
Hamburg, Germany, 20246
Site Reference ID/Investigator# 45027
Heidelberg, Germany, 69120
Site Reference ID/Investigator# 45024
Munich, Germany, 81675
Site Reference ID/Investigator# 45126
Bekescsaba, Hungary, 5600
Site Reference ID/Investigator# 45121
Budaors, Hungary, 2040
Site Reference ID/Investigator# 45127
Dunaujvaros, Hungary, 2400
Site Reference ID/Investigator# 45115
Gyula, Hungary, 5700
Site Reference ID/Investigator# 45116
Sopron, Hungary, 9400
Site Reference ID/Investigator# 45114
Szeged, Hungary, 6720
Site Reference ID/Investigator# 45130
Bologna, Italy, 40138
Site Reference ID/Investigator# 45129
Padova, Italy, 35128
Site Reference ID/Investigator# 45128
Verona, Italy, 37126
Sponsors and Collaborators
Abbott Products
Quintiles, Inc.
Data Map GmbH
Layout table for investigator information
Study Director: Guenter Krause, MD Abbott Products

Layout table for additonal information
Responsible Party: Gregor Eibes/Clinical Trial Manager, Abbott Products Identifier: NCT00535756    
Other Study ID Numbers: S245.4.008
2005-004854-29 ( EudraCT Number )
First Posted: September 26, 2007    Key Record Dates
Last Update Posted: August 18, 2011
Last Verified: August 2011
Keywords provided by Abbott:
Pancreatic Exocrine Insufficiency After Pancreatic Surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Exocrine Pancreatic Insufficiency
Pancreatic Diseases
Digestive System Diseases
Gastrointestinal Agents